AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
ASTRAZENECA PLC
Financials through fiscal 2025, year ended Dec 31, 2025
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 25.1
- Dividend yield
- 1.91%
Margins
Share of revenue, fiscal years 2015 to 2025
Gross margin
81.9%+1.8 pts over 5 years
Operating margin
23.4%+4.0 pts over 5 years
Net margin
17.4%+5.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +8.6% | +9.8% | +17.2% | +9.0% | |
| Gross profit | +9.7% | +14.6% | +17.7% | +9.1% | |
| Operating income | +37.4% | +54.1% | +21.6% | +12.8% | |
| Net income | +45.3% | +46.0% | +26.2% | +13.7% | |
| EPS, diluted | +45.3% | +45.8% | +21.8% | +11.4% | |
| Free cash flow | +18.4% | +10.5% | +25.1% | +19.4% | |
| Dividend per share | +5.4% | +2.6% | +2.3% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 21.0% | 22.2% | 22.9% | |
| Return on assets | 5.7% | 5.0% | 9.4% | |
| Current ratio | 0.87 | 0.96 | 0.94 | |
| Debt to equity | 1.13 | 1.26 | 0.57 | |
| Interest coverage | 3.5× | 4.0× | 8.1× | |
| Inventory turnover | 1.8× | 1.5× | 1.8× | |
| Capex to revenue | 6.3% | 3.6% | 4.8% | |
| Diluted shares | 1.27B | 1.31B | 1.56B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Astrazeneca generated $52.55B from operations and spent $31.33B on capital expenditure, dividends and share buybacks. 26% of that went back into the business.
Generated
$52.55B
Used
$31.33B
Capital expenditure$8.28B26%Dividends$22.30B71%Share buybacks$751.00M2%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin17.4%
×Asset turnover0.54×
×Equity multiplier2.44×
=Return on equity, FY202522.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 17.4% | 0.54× | 2.44× | 22.9% |
| FY2024 | 13.0% | 0.53× | 2.57× | 17.6% |
| FY2023 | 13.0% | 0.46× | 2.59× | 15.6% |
| FY2022 | 7.4% | 0.44× | 2.65× | 8.6% |
| FY2021 | 0.3% | 0.43× | 3.14× | 0.4% |
| FY2020 | 12.0% | 0.42× | 4.46× | 22.2% |
| FY2019 | 5.5% | 0.40× | 4.77× | 10.4% |
| FY2018 | 9.8% | 0.36× | 4.52× | 15.7% |
| FY2017 | 13.4% | 0.36× | 4.22× | 20.1% |
| FY2016 | 15.2% | 0.38× | 3.68× | 21.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
9of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$10.23B
- Cash generatingOperating cash flow above zero$14.58B
- Return on assets improvedROA up on the prior year7.0% → 9.8%
- Earnings backed by cashOperating cash flow above net income$14.58B vs $10.23B
- Less leverageLong-term debt to assets fell25.5% → 21.7%
- Better liquidityCurrent ratio rose0.93 → 0.94
- No dilutionShare count did not rise1.56B → 1.56B
- Gross margin improvedGross margin up on the prior year81.12% → 81.90%
- More efficientAsset turnover rose0.53 → 0.56